In our latest Lab on a Chip article entitled “Enabling continuous immune cell recirculation on a microfluidic array to study immunotherapeutic interactions in a recapitulated tumour microenvironment,” we developed a tumor chip system that recapitulated the dynamics between immunotherapeutic agents (anti-PD-LI antibody), tumor microenvironment (triple-negative breast cancer cells, tumor stroma and endothelium) and immune cells (CD8+ T cell).
Emerging CRISPR technologies provide new opportunities to advance gene therapy. Efficient delivery and gene targeting specificity are the two keys to realizing the full potential of CRISPR gene editing. We are tackling these two main barriers via both delivery and molecular engineering innovations.
We are building new toolkits ranging from viral vectors, nanomaterials, cells and physical methods to improve the drug and gene delivery efficiency and specificity. Our bioengineering approaches help us address the transport questions in different challenging disease and tissue targets.
Our in vitro, high-throughput tissue and tumor chips allow us to study the interactions between cells, drug-cell, and cell-microenvironment. These are more physiologically relevant platforms for evaluating the pharmacokinetics of biologics.
